March 17, 2009 – Twelve-month data from the ATLANTA Trial shows that the CATANIA Coronary Stent System with NanoThin Polyzene-F offers sustained benefit in the treatment of de novo coronary lesions and maximizes endothelialization, while reducing restenosis, thrombogenicity, and the need for long-term dual-antiplatelet therapy.

March 17, 2009 - Edwards Lifesciences Corp. announced it has completed enrollment in the 350-patient nonsurgical study arm of its PARTNER Trial for the Edwards SAPIEN transcatheter aortic heart valve.

March 17, 2009 – Sorin Group recently announced the enrollment of the first three patients in a clinical trial aimed at obtaining European market approval for its Perceval S Sutureless Aortic Heart Valve.

March 17, 2009 - eCardio Diagnostics has launched an Academic Medicine initiative to provide a tailored offering to university-based health systems, marking the first time an arrhythmia monitoring company has addressed the unique workflow, teaching and research responsibilities of academic medical centers.

The eCardio Academic Medicine service offers:

March 16, 2009 - St. Jude Medical Inc. today announced FDA clearance of the newest version of the Merlin.net Patient Care Network (PCN), a secure, Internet-based remote care system for patients with implanted medical devices.

March 17, 2009 - Clinical pharmacology company Cetero Research and centralized cardiac testing company Cardiocore announced today a global strategic alliance to optimize the design, conduct and reporting of cardiac safety studies.

March 16, 2009 - LUMEDX Corp. and Mennen Medical said today they signed a strategic partnership agreement to provide a total, integrated cath lab data solution and seamless stream of hemodynamic cardiovascular patient data to their customers.

Patients with chronic conditions such as congestive heart failure use Honeywell HomMed’s Genesis DM telehealth monitor from the comfort of their own homes to daily measure vital signs such as heart rate, blood pressure and weight.

March 16, 2009 - TeraRecon reported that it has achieved greater than 10,000 licensed concurrent users globally for its Aquarius advanced visualization solution, and claims that the figure gives the company the largest market share in the direct-to-end-user market for advanced visualization.

March 16, 2009 - Cordis Corp. said today it plans to launch a global, head-to-head, randomized clinical trial called NEVO II, which will compare the NEVO sirolimus-eluting coronary stent to the XIENCE V everolimus-eluting coronary stent.

Cordis and Conor Medsystems LLC are sponsors of the study.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now